S8 Ep9: Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
On this episode of Targeted Talks, Lyudmila Bazhenova, MD, discusses the FDA’s expanded label approval of taletrectinib (Ibtrozi) for ROS1-positive non–small cell lung cancer (NSCLC). She explains that the approval is based on data already presented at the 2026 AACR Annual Meeting, which showed efficacy in both TKI-naive and TKI-pretreated patients with longer follow-up. In TKI-naive patients, pooled analysis showed an intracranial overall response rate of 76.5%, a median duration of response of 49.7 months, and a median progression-free survival of 46.1 months, with no new safety signals…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.